Transplant
Feature
Extraordinary Patients Inspired Father of Cancer Immunotherapy
Renowned researcher, Dr. Steven A. Rosenberg, describes his path to pioneering the use of immunotherapies in treating cancer.
Conference Coverage
High Marks for New CAR T Toxicity Grading Tool
A real-world study demonstrates the benefits of a new grading system to assess hematotoxicities across disease types following CAR T-cell...
Latest News
Patient-Reported Outcomes Predict Mortality in Cutaneous Chronic GVHD
Study findings are relevant to dermatologists in academic and transplant centers and the community who provide skin cancer screenings or other...
Conference Coverage
B-ALL: CAR-T Outperforms Novel Therapies
Real-world patients with B-ALL who relapsed post transplant showed significantly better outcomes with CAR T-cell therapy versus novel alternative...
News
Top US Oncology Regulator Seeks Changes in Drug Studies
FDA and European officials seek to build on recent successes treating blood cancers in order to expand treatment options for other cancers.
Feature
ALL: When Should MRD Trigger Stem Cell Transplants?
Hematologists disagree over the meaning of minimal residual disease in relapsed/refractory and older patients.
Conference Coverage
In Transplant-Ineligible Myeloma, This Frontline Tx Is Better
New study finds a top performer among “preferred” treatment combos for patients with multiple myeloma who can’t get stem cell transplants.
Latest News
GVHD raises vitiligo risk in transplant recipients
Graft-versus-host disease appears to raise vitiligo risk in transplant recipients, particularly those who receive hematopoietic stem cell...
Conference Coverage
No Benefit to Salvage Transplant in R/R Multiple Myeloma
Fresh data confirm that a second transplant does not improve survival vs. standard two-drug regimen for relapsed myeloma.
Conference Coverage
MRD status predicts transplant benefit in NPM1-mutated AML
Certain patients with NPM1-mutated acute myeloid leukemia and measurable residual disease were shown to benefit from transplantation.
Conference Coverage
Sickle Cell: Good Outcomes for Haploidentical Transplants
Overall 2-year survival was 95% in a small, “robust” phase-2 trial of children and adults with sickle cell disease.